What is the value of oncology medicines?
Coverage with evidence development (CED), rather than quality-adjusted-life-year (QALY) thresholds, offers the best way forward in balancing evidence-based policy for new oncology products with the needs of developers, payers, physicians and patients.
Tufts University School of Medicine, Center for the Study of Drug Development, Boston, Massachusetts, USA.
Joshua
J
Cohen
William
W
Looney
D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use*; D020811:Biomedical Technology / Q000191:economics; D003362:Cost-Benefit Analysis; D006287:Health Planning Guidelines; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000191:economics; D056687:Off-Label Use; D019057:Quality-Adjusted Life Years
D000970:Antineoplastic Agents